ArticleClinical medicine insights. Case reports2026
Successful Management of Tyrosine Kinase Inhibitor-Induced Bone Marrow Aplasia in Chronic Phase Chronic Myeloid Leukemia with Ponatinib: A Case Report and Literature Review.
Article in Clinical medicine insights. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tyrosine kinase inhibitors (TKIs) represent the standard of care for chronic myeloid leukemia (CML). Although cytopenias are frequent, severe and persistent bone marrow aplasia is exceedingly rare, with limited evidence to guide management in non-transplant candidates. Case presentation: A 35-year-old man with chronic-phase CML developed persistent bone marrow aplasia after sequential treatment with imatinib and dasatinib. Despite dose reductions and supportive measures, profound pancytopenia persisted, leading to treatment cessation. In the absence of a matched donor and response ( Discussion: TKI-associated bone marrow aplasia has been reported with agents such as imatinib, dasatinib, and nilotinib. Proposed mechanisms include off-target inhibition of hematopoietic kinases (eg, c-KIT, PDGFR) and suppression of malignant clones preceding normal marrow recovery. Management typically involves discontinuation, transfusion support, immunosuppressive therapy, or transplantation. In this case, ponatinib proved effective and tolerable as salvage therapy after previous TKI-induced marrow aplasia. Conclusion: TKI-induced bone marrow aplasia is an uncommon but serious toxicity in CML. This case supports the potential role of ponatinib as an effective salvage option following severe TKI-related marrow toxicity, particularly in patients who are not candidates for allogeneic transplantation. Further clinical experience and larger studies are needed to better define optimal management strategies for this rare but serious complication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.